Alternative splicing in lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 6, 2009, Pages 674-678

  Pio, Ruben ^a,b   Montuenga, Luis M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alternative splicing; Bcl x; CD44; HnRNP; Lung cancer; RNA binding protein

Indexed keywords

CISPLATIN; EMETINE; GEMCITABINE; PROTEIN BCL X; PROTEIN BCL XL; RIBONUCLEOPROTEIN;

APOPTOSIS; CANCER DIAGNOSIS; DNA SPLICING; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GENE; ALTERNATIVE RNA SPLICING; GENETICS; LUNG TUMOR; PATHOLOGY;

ALTERNATIVE SPLICING; HUMANS; LUNG NEOPLASMS;

EID: 67849087126     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a520dc     Document Type: Article

References (69)

1. Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470-476. (Pubitemid 352759009)
2. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005;42:342-357. (Pubitemid 40271278)
3. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378-386.
4. Johnson JM, Castle J, Garrett-Engele P, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302:2141-2144. (Pubitemid 38017950)
5. Clark TA, Sugnet CW, Ares MJ. Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 2002; 296:907-910.
6. Anton MA, Gorostiaga D, Guruceaga E, et al. SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biol 2008;9:R46. (Pubitemid 351943983)
7. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8:349-357. (Pubitemid 46464532)
8. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004;37:584-594.
9. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-7654.
10. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007;39:1432-1449. (Pubitemid 47031033)
11. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005;19:1-13. (Pubitemid 40884653)
12. Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosisregulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996;73:1193-1200. (Pubitemid 26162332)
13. Groeger AM, Esposito V, De Luca A, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004;44:54-63. (Pubitemid 38174871)
14. Karczmarek-Borowska B, Filip A, Wojcierowski J, et al. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 2006;51:61-69. (Pubitemid 43088625)
15. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-579. (Pubitemid 35425379)
16. Pirinen R, Hirvikoski P, Bohm J, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol 2000;31:1088-1095. (Pubitemid 30738040)
17. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998;58:1108-1110. (Pubitemid 28183192)
18. Nguyen VN, Mirejovsky T, Melinova L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000;47:400-408.
19. Givehchian M, Woerner SM, Lacroix J, et al. Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene 1996;12: 1137-1144. (Pubitemid 26104457)
20. Carbognani P, Spaggiari L, Romani A, et al. Expression of human CD44v6 in non-small-cell lung cancer. Eur Surg Res 1998;30:403-408. (Pubitemid 28561059)
21. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14. (Pubitemid 46038884)
22. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003;63: 7056-7061. (Pubitemid 37413439)
23. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-30347. (Pubitemid 36962428)
24. Li R, An SJ, Chen ZH, et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum Pathol 2008;39:1792-1801.
25. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-289. (Pubitemid 43166034)
26. Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003;41:131-143. (Pubitemid 36842776)
27. Zerbe LK, Pino I, Pio R, et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 2004;41:187-196. (Pubitemid 39552706)
28. Peebles KA, Dwyer-Nield LD, Malkinson AM. Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia. Mol Carcinog 2007;46:887-900.
29. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997; 3:2237-2246. (Pubitemid 28133141)
30. Sueoka E, Sueoka N, Iwanaga K, et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer 2005;48:77-83. (Pubitemid 40381002)
31. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14:185-193. (Pubitemid 46355578)
32. Pio R, Zudaire I, Pino I, et al. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res 2004;64:4171-4179. (Pubitemid 38802420)
33. Castano Z, Vergara-Irigaray N, Pajares MJ, Montuenga LM, Pio R. Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int J Cancer 2008;122:1512-1520. (Pubitemid 351294959)
34. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 2008;40:1240-1244.
35. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-479.
36. Leech SH, Olie RA, Gautschi O, et al. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 2000;86:570-576. (Pubitemid 30249740)
37. Simoes-Wust AP, Hopkins-Donaldson S, Sigrist B, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 2004;14:199-209. (Pubitemid 39362487)
38. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999;17:1097-1100.
39. Boon-Unge K, Yu Q, Zou T, Zhou A, Govitrapong P, Zhou J. Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem Biol 2007;14:1386-1392. (Pubitemid 350262840)
40. Chalfant CE, Rathman K, Pinkerman RL, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277:12587-12595. (Pubitemid 34952617)
41. Sen S, Sharma H, Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 2005;331:1245-1252. (Pubitemid 40692490)
42. Chan HC, Kuo SC, Liu SC, Liu CH, Hsu SL. 4-Fluoro-N-butylphenylacetamide: a synthetic phenylacetate derivative that upregulates Bcl- X(S), activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells. Cancer Lett 2002;186:211-221.
43. DiFeo A, Feld L, Rodriguez E, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 2008;68:965-970. (Pubitemid 351272212)
44. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-579. (Pubitemid 36182586)
45. Lo KM, Lan Y, Lauder S, et al. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 2007;56:447-457. (Pubitemid 46204531)
46. Calarco JA, Saltzman AL, Ip JY, Blencowe BJ. Technologies for the global discovery and analysis of alternative splicing. Adv Exp Med Biol 2007;623:64-84.
47. Gardina PJ, Clark TA, Shimada B, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006;7:325. (Pubitemid 46165475)
48. French PJ, Peeters J, Horsman S, et al. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 2007;67:5635-5642. (Pubitemid 46984994)
49. Thorsen K, Sorensen KD, Brems-Eskildsen AS, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008;7:1214-1224. (Pubitemid 352038268)
50. Cheung HC, Baggerly KA, Tsavachidis S, et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008;9:216. (Pubitemid 351785140)
51. Xi L, Feber A, Gupta V, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008;36:6535-6547.
52. Wang L, Lin SH, Wu WG, et al. C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. Clin Cancer Res 2000;6:2988-2993. (Pubitemid 30637719)
53. Nakagawa K, Noguchi Y, Uenaka A, et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005;11:5496-5503. (Pubitemid 41060826)
54. Ali Eldib AM, Ono T, Shimono M, et al. Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int J Cancer 2004;108:558-563. (Pubitemid 38036656)
55. Wang T, Fan L, Watanabe Y, et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001;20:7699-7709. (Pubitemid 33121943)
56. Honda K, Yamada T, Seike M, et al. Alternative splice variant of actinin-4 in small cell lung cancer. Oncogene 2004;23:5257-5262. (Pubitemid 38980358)
57. Malentacchi F, Simi L, Nannelli C, et al. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer 2008. [Epub ahead of print].
58. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11:1005-1011.
59. Tzao C, Tsai HY, Chen JT, Chen CY, Wang YC. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. Eur J Cancer 2004;40:2175-2183. (Pubitemid 39165553)
60. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Oncodevelopmental regulation of the alternative splicing of fibronectin premessenger RNA in human lung tissues. Cancer Res 1990;50:1075-1078. (Pubitemid 20083989)
61. Khan ZA, Caurtero J, Barbin YP, Chan BM, Uniyal S, Chakrabarti S. ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res 2005;31:701-711. (Pubitemid 41359310)
62. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-4049. (Pubitemid 32681609)
63. Weng MW, Lai JC, Hsu CP, et al. Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines. Environ Mol Mutagen 2005;46: 1-11.
64. Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008;99:590-594. (Pubitemid 351228578)
65. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2008. [Epub ahead of print].
66. Coulson JM, Edgson JL, Woll PJ, Quinn JP. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 2000;60:1840-1844.
67. Kim HJ, Hwang JY, Kim HJ, et al. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin Cancer Res 2007;13:2577-2583.
68. Oh Y, Proctor ML, Fan YH, et al. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene 1998;17:1141-1148. (Pubitemid 28444598)
69. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP. Tissuespecific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 1998;29:910-914. (Pubitemid 28422038)